View live charts, options flow & technicals for Johnson & Johnson →
Open Dashboard
Johnson & Johnson (JNJ) is a healthcare company in the drug manufacturers - general industry with $97.93B in trailing revenue trading at a 31.3× trailing P/E — analyst consensus: buy.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Key Statistics
Market Cap
$648.67B
Revenue (TTM)
$97.93B
EPS (TTM)
$8.61
EPS (Fwd est.)
$12.14
Employees
138,200
Trailing P/E
31.26
Forward P/E
22.18
PEG Ratio
2.82
Price / Sales
6.62
Price / Book
7.63
EV / EBITDA
19.41
Beta (5Y)
0.23
Analyst Consensus
Consensus
Buy
Analyst Price Target
+3.2% upside
Target: $277.91
Annual Revenue & Net Income
RevenueNet Income
'22
$79.99B
$17.94B
'23
$85.16B
$35.15B
'24
$88.82B
$14.07B
'25
$94.19B
$26.80B
Earnings History
Quarter
Actual EPS
Estimate
Result
Jul 2026
$2.90
$2.85
Beat (+1.6%)
Apr 2026
$2.70
$2.68
Beat (+0.8%)
Jan 2026
$2.46
$2.46
Miss (-0.1%)
Oct 2025
$2.80
$2.76
Beat (+1.5%)
Next Earnings Report
Johnson & Johnson is next expected to report earnings on 13 Oct 2026.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases…
What is JNJ's market cap?
Johnson & Johnson has a market capitalization of approximately $648.67B.
What is JNJ's P/E ratio?
Johnson & Johnson trades at a trailing P/E ratio of 31.3x and a forward P/E of 22.2x, which is above the broad market average of ~25x.
How much revenue does JNJ generate?
Johnson & Johnson generated $97.93B in trailing 12-month revenue.
What do analysts say about JNJ?
The analyst consensus rating for Johnson & Johnson is buy, with a mean price target of $277.91. That implies +3.2% upside from the current price.
When does JNJ report earnings?
Johnson & Johnson is next scheduled to report earnings on 13 Oct 2026.
Does JNJ pay a dividend?
Yes. Johnson & Johnson pays a dividend with a current yield of 1.99%, at an annual rate of $5.36 per share.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Johnson & Johnson on Apsis Markets.